Compare MBINM & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBINM | BRTX |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | 663 | N/A |
| Industry | Major Banks | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 9.7M |
| IPO Year | N/A | N/A |
| Metric | MBINM | BRTX |
|---|---|---|
| Price | $25.36 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 63.9K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | N/A | $139.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.70 |
| 52 Week Low | N/A | $0.98 |
| 52 Week High | N/A | $2.55 |
| Indicator | MBINM | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.35 | 42.99 |
| Support Level | $24.70 | $1.07 |
| Resistance Level | $25.11 | $1.16 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 97.06 | 71.22 |
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.